论文部分内容阅读
目的研究P糖蛋白(P -gp)、谷胱苷肽转移酶π(GST-π)在非小细胞肺癌(NSCLC)组织的表达及其与预后的关系。方法选择2001-05～2001-10辽宁省肿瘤医院有完整随访记录和TNM分期NSCLC病例62例,采用福州近新公司生产的SP即用型试剂盒及即用型抗P gp、GSTπ进行了免疫组化检测。应用χ2检验,t检验进行统计学分析。结果P gp阳性表达率腺癌65.7%(23/35例),鳞癌37.0%(10/27例),(χ2=5.035,P<0.05)。GSTπ阳性表达率腺癌54.3%(19/35例),鳞癌85.2%(23/27例)(χ2=6.66,P<0.05)。随P- gp、GSTπ阳性表达强度增加,患者生存期缩短,差异有显著性(t值分别为2.851和3.1458)。结论P -gp、GSTπ共同参与了肺癌耐药机制,P -gp、GSTπ在肺癌耐药机制中有共同高表达,P- gp在腺癌组织上中高表达,与临床上肺腺癌化疗不敏感一致。GSTπ在鳞癌组织上中高表达,表明GSTπ是人体鳞癌的一个较好的标志耐药蛋白,也可作为肺鳞癌的诊断指标。随P gp、GST-π表达阳性增高患者生存期缩短。
Objective To study the expression of P-gp and GST-π in non-small cell lung cancer (NSCLC) and its relationship with prognosis. Methods Totally 62 cases of NSCLC with complete follow-up records and TNM staging were selected from Liaoning Provincial Tumor Hospital from 2001-05 to 2001-10. The SP-ready kit and the ready-to-use anti-Pgp, GSTπ Tissue testing. Application χ2 test, t test for statistical analysis. Results The positive rate of Pgp was 65.7% (23/35) in adenocarcinoma and 37.0% (10/27) in squamous cell carcinoma (χ2 = 5.035, P <0.05). The positive rate of GSTπ was 54.3% (19/35) in adenocarcinoma and 85.2% (23/27) in squamous cell carcinoma (χ2 = 6.66, P <0.05). With the P-gp, GSTπ positive expression intensity increased, patients with shortened survival, the difference was significant (t values were 2.851 and 3.1458, respectively). Conclusion P-gp and GSTπ are involved in the mechanism of drug resistance in lung cancer. P-gp and GSTπ are overexpressed in the mechanism of lung cancer drug resistance. P-gp is overexpressed in adenocarcinoma and is not sensitive to clinical chemotherapy of lung adenocarcinoma Consistent. GSTπ is highly expressed in squamous cell carcinoma tissues, indicating that GSTπ is a good marker of human squamous cell carcinoma and can be used as a diagnostic indicator for squamous cell carcinoma of the lung. With P gp, GST-π expression was increased in patients with shortened survival.